PMID- 37842336
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231020
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 16
DP  - 2023
TI  - Formate Might Be a Novel Potential Serum Metabolic Biomarker for Type 2 Diabetic 
      Peripheral Neuropathy.
PG  - 3147-3160
LID - 10.2147/DMSO.S428933 [doi]
AB  - BACKGROUND: As one of the most frequent complications of type 2 diabetes mellitus 
      (T2DM), diabetic peripheral neuropathy (DPN) shows a profound impact on 50% of 
      patients with symptoms of neuropathic pain, numbness and other paresthesia. No 
      valid serum biomarkers for the prediction of DPN have been identified in the 
      clinic so far. This study is to investigate the potential serum biomarkers for 
      DPN firstly based on (1)H-Nuclear Magnetic Resonance ((1)H-NMR)-based 
      metabolomics technique. METHODS: Thirty-six patients enrolled in this study were 
      divided into two groups: 18 T2DM patients without DPN (T2DM group) and 18 T2DM 
      patients with DPN (DPN group). Serum metabolites were measured via (1)H-NMR 
      spectroscopy. Bioinformatic approaches including principal component analysis 
      (PCA), orthogonal partial least squares-discriminant analysis (OPLS-DA), 
      independent sample t-test, Fisher's test, Pearson and Spearman correlation 
      analysis, Stepwise multiple linear regression analysis and receiver operating 
      characteristic (ROC) curve analysis were used to identify the potential altered 
      serum biomarkers. RESULTS: A total of 20 metabolites were obtained and further 
      analyzed. Formate was identified as the only potential biomarker that decreased 
      in the DPN group with statistical significance after multiple comparisons 
      (p<0.05). Formate also displayed a negative relationship with some elevated 
      clinical markers in DPN. ROC curve analysis showed a good discriminative ability 
      for formate in DPN with an area under the curve (AUC) value of 0.981. CONCLUSION: 
      Formate could be considered a potential serum metabolic biomarker for DPN. The 
      reduced level of formate in DPN may be associated with mitochondrial dysfunction 
      and gut microbiota alteration. Monitoring the level of serum formate would be an 
      important strategy for the early diagnosis of DPN and a supplement of formate may 
      be a promising treatment for DPN in the future.
CI  - (c) 2023 Xu et al.
FAU - Xu, Weisheng
AU  - Xu W
AUID- ORCID: 0000-0001-6649-6297
AD  - Department of Pain Medicine, Shanghai Tenth People's Hospital, Tongji University 
      School of Medicine, Shanghai, 200072, People's Republic of China.
AD  - School of Medicine, Tongji University, Shanghai, 200331, People's Republic of 
      China.
FAU - Xue, Wangsheng
AU  - Xue W
AD  - Department of Pain Medicine, Shanghai Tenth People's Hospital, Tongji University 
      School of Medicine, Shanghai, 200072, People's Republic of China.
FAU - Zhou, Zeyu
AU  - Zhou Z
AD  - School of Life Sciences, Fudan University, Shanghai, 200433, People's Republic of 
      China.
FAU - Wang, Jiying
AU  - Wang J
AD  - Department of Pain Medicine, Shanghai Tenth People's Hospital, Tongji University 
      School of Medicine, Shanghai, 200072, People's Republic of China.
FAU - Qi, Hui
AU  - Qi H
AD  - Department of Pain Medicine, Shanghai Tenth People's Hospital, Tongji University 
      School of Medicine, Shanghai, 200072, People's Republic of China.
FAU - Sun, Shiyu
AU  - Sun S
AD  - Department of Pain Medicine, Shanghai Tenth People's Hospital, Tongji University 
      School of Medicine, Shanghai, 200072, People's Republic of China.
FAU - Jin, Tong
AU  - Jin T
AD  - Department of Pain Medicine, Shanghai Tenth People's Hospital, Tongji University 
      School of Medicine, Shanghai, 200072, People's Republic of China.
FAU - Yao, Ping
AU  - Yao P
AD  - Department of Pain Medicine, Shanghai Tenth People's Hospital, Tongji University 
      School of Medicine, Shanghai, 200072, People's Republic of China.
FAU - Zhao, Jian-Yuan
AU  - Zhao JY
AD  - Institute for Developmental and Regenerative Cardiovascular Medicine, 
      MOE-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, 
      Shanghai Jiao Tong University School of Medicine, Shanghai, 200090, People's 
      Republic of China.
FAU - Lin, Fuqing
AU  - Lin F
AD  - Department of Pain Medicine, Shanghai Tenth People's Hospital, Tongji University 
      School of Medicine, Shanghai, 200072, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20231010
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC10576463
OTO - NOTNLM
OT  - 1H-NMR
OT  - diabetic peripheral neuropathy
OT  - formate
OT  - metabolomics
OT  - type 2 diabetes mellitus
OT  - uric acid
COIS- The authors report no conflicts of interest in this work.
EDAT- 2023/10/16 06:48
MHDA- 2023/10/16 06:49
PMCR- 2023/10/10
CRDT- 2023/10/16 04:52
PHST- 2023/07/04 00:00 [received]
PHST- 2023/10/04 00:00 [accepted]
PHST- 2023/10/16 06:49 [medline]
PHST- 2023/10/16 06:48 [pubmed]
PHST- 2023/10/16 04:52 [entrez]
PHST- 2023/10/10 00:00 [pmc-release]
AID - 428933 [pii]
AID - 10.2147/DMSO.S428933 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2023 Oct 10;16:3147-3160. doi: 10.2147/DMSO.S428933. 
      eCollection 2023.